Year: 2025
Type: article
Abstract: Respiratory Syncytial Virus (RSV) is a leading cause of serious lung infections in infants and young children, especially during the winter months. For decades, preventative options were limited, costly, or only available to babies at high-risk. The FDA approved Enflonsia (clesrovimab-cfor) in June 2025, given as a single injection to protect infants thorough their first RSV season. Since it is designed for broader infant use and can be distributed through programs such as Vaccines for Children, Enflonsia may help close long-standing gaps in RSV prevention.
Source: Transformative Medicine
Authors: Katherine Ghattas, Rileigh Smith, Amanda Rawa
Institution: Reading Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4414655000
FWCI:
Cites:
Cited by:
Related to: